Latest Content

Study Confirms Lenvima’s Benefits in Thyroid Cancer

September 19th 2024, 9:00pm

By Morgan Bayer

Article

First-time treatment with Lenvima continues to outperform other treatments for thyroid cancer.

Navigating the ‘Ever-Evolving Trajectory’ of Metastatic Breast Cancer

September 19th 2024, 7:00pm

By Darlene Dobkowski, MA

Article

Through communication and education, patients with metastatic breast cancer may be able to balance treatment with quality of life.

How Cancer Bracelets Can Help Spread Awareness

September 19th 2024, 5:00pm

By Laura Yeager

Article

I bought 14 precious cancer bracelets in a discount store to help spread awareness about cancer — something I’m ready to speak out about.

Infections May Impact Survival, Quality of Life in Patients With MDS

September 19th 2024, 3:00pm

By Alex Biese

Article

While infections pose a risk for morbidity and mortality among patients with MDS, more needs to be studied about the topic, researchers urged.

Braftovi Regimen Is Promising in Metastatic Colorectal Cancer

September 19th 2024, 1:00pm

By Jason Broderick

Article

In patients with BRAF V600E-mutant metastatic colorectal cancer, a combination of Braftovi, Erbitux and chemotherapy showed promising antitumor activity.

Patients With Lower-Risk Myelofibrosis May Respond to Jakafi

September 18th 2024, 9:00pm

By Darlene Dobkowski, MA

Article

Although Jakafi has been approved for patients with higher-risk myelofibrosis, those with lower-risk disease may also benefit from this treatment.

Why Transfusion Independence Matters for Patients With MDS

September 18th 2024, 7:00pm

By Alex Biese

Article

An expert explained the burden that red blood cell transfusions can place on patients with MDS.

Healing and Reflecting on My Ovarian Cancer Experience

September 18th 2024, 5:00pm

By Julie S. Brokaw

Article

The past 15 months have been challenging regarding treatment for my ovarian cancer. But today, my goal is to focus on healing my mind, body and soul.

Trodelvy May Improve Responses in Bladder Cancer Subtype

September 18th 2024, 3:00pm

By Spencer Feldman

Article

Trodelvy in locally advanced or metastatic urothelial cancer may provide another option for those whose disease progressed after checkpoint inhibitors.

Kisqali Plus Aromatase Inhibitor Shows Benefits in HR+/HER2- Breast Cancer

September 18th 2024, 1:00pm

By Russ Conroy

Article

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free benefits in a breast cancer subset.

FDA Approves Keytruda Plus Chemo for Pleural Mesothelioma Subset

September 17th 2024, 11:02pm

By Darlene Dobkowski, MA

Article

Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on findings from the KEYNOTE-483 trial.

Vonjo Improves Thrombocytopenia, Anemia in Patients With Myelofibrosis

September 17th 2024, 9:00pm

By Jax DiEugenio

Article

Vonjo was also shown to improve overall survival in patients with myelofibrosis treated with Vonjo in the real-world setting.

FDA Approves Kisqali Regimen for HR+/HER2- Early Breast Cancer

September 17th 2024, 6:09pm

By Alex Biese

Article

Kisqali has been FDA-approved with an aromatase inhibitor as postsurgical treatment for some with early breast cancer at a high risk of recurrence.

Strangers, Manners and a Personal Side of Breast Cancer

September 17th 2024, 5:00pm

By Doris Cardwell

Article

I am still struggling to navigate the intrusive questions of well-meaning strangers 17 years after surviving inflammatory breast cancer.

Adaptive NSCLC Study Fails to Produce Improved Results, Clinical Benefits in Some

September 17th 2024, 3:02pm

By Dylann Cohn-Emery

Article

Imfinzi with monalizumab and ceralasertib showed promising long-term benefits in advanced NSCLC, but no other combinations significantly improved results.